Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What’s the Difference? Ali Berkant AvciEugen FeistGerd Rüdiger Burmester Leading Article 29 November 2018 Pages: 531 - 546
Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier Danica B. StanimirovicJagdeep K. SandhuWill J. Costain Leading Article Open access 10 October 2018 Pages: 547 - 559
Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors Johnny N. Mahlangu Leading Article 14 November 2018 Pages: 561 - 570
Recombinant Antibody Production in CHO and NS0 Cells: Differences and Similarities Venkata Gayatri DharaHarnish Mukesh NaikMichael J. Betenbaugh Review Article 30 November 2018 Pages: 571 - 584
Comparative Effectiveness and Safety of Monoclonal Antibodies (Bevacizumab, Cetuximab, and Panitumumab) in Combination with Chemotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis Wânia Cristina da SilvaVânia Eloisa de AraujoEli Iola Gurgel Andrade Systematic Review Open access 30 November 2018 Pages: 585 - 606
Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study Cristina ScavoneMaurizio SessaAnnalisa Capuano Original Research Article Open access 20 October 2018 Pages: 607 - 617
In-Use Physicochemical and Biological Stability of the Trastuzumab Biosimilar CT-P6 Upon Preparation for Intravenous Infusion Su Jung KimJoon Won LeeJi Young Kim Short Communication 02 November 2018 Pages: 619 - 625
Darvadstrocel: A Review in Treatment-Refractory Complex Perianal Fistulas in Crohn’s Disease Lesley J. Scott Adis Drug Evaluation 08 October 2018 Pages: 627 - 634
PF-06438179/GP1111: An Infliximab Biosimilar Zaina T. Al-Salama Adis Biosimilar Brief Open access 04 October 2018 Pages: 639 - 642
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar Zaina T. Al-Salama Correction Open access 15 November 2018 Pages: 643 - 643